Dell

Dell Technologies Capital, newly out of stealth, invested in Edico Genome because it believes whole-genome sequencing is almost ready to take off on a wide scale.

Sequencing IT developer Edico said it will use the funding to build out its Dragen bioinformatics processor and step up marketing efforts.

The combined product includes Edico’s Dragen bioinformatics processor integrated into a Dell server, as well as Dell EMC’s Isilon storage.

Dell plans to begin allowing clinical customers to store genomic datasets alongside patients' medical imaging data this spring.

The High Performance Computing Solution for Genomics is a pre-configured computer hardware platform specifically designed for clinical genomic analysis.

The funding will be used to optimize a high-performance computing infrastructure for the analysis and storage of genetic data.

NEW YORK (GenomeWeb) – Dell, the Translational Genomics Research Institute, and Terascala will provide the National Cancer Institute with a high performance computing system, programming applications, expertise, and software to support genomics research projects, TGen said today.

This week, Terascala said that it has released a new version of the Intelligent Storage Bridge (ISB), a high-performance data-movement appliance which the company first introduced last fall to help its customers, especially those in the genomics arena, move large quantities of da

DNAnexus has launched a developer program that offers bioinformaticians and software engineers the technical and support resources needed to create and integrate data analysis applications on its platform.

By Uduak Grace Thomas
Dell said this week that it is providing funding and a private cloud infrastructure to support pediatric cancer research using gene-expression profiling and, eventually, next-generation sequencing.

Pages

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.